RAPS test 3 with 100% correct Answers
Blood iiCenter iiABC iihas iijust iiopened iiin iia iiMidwestern iistate. iiIt iiplans iito iimanufacture
iiblood iiand iiblood iiproducts iifrom iivolunteer iiblood iidonors iiand iioffer iithese iiproducts
iifor iisale iito iilocal iidialysis iiclinics iiand iihospitals iiin iiother iistates. iiBlood iiCenter iiABC
iimust:
(A) iiRegister iiwith iiFDA iiwithin iifive iidays iiafter iibeginning iioperations iiand iiprovide iia
iicurrent iiproduct iilist iiof iiall iiproducts iimanufactured, iiprepared, iiprocessed iiand
iidistributed
(B) iiWait iito iidistribute iiany iiblood iiproducts iiuntil iithe iisuccessful iicompletion iiof iia iiGMP
iiinspection iiby iiFDA
(C) iiSubmit iian iiNDA iito iiFDA iiprior iito iidistribution iiof iiany iiblood iiproducts iiin iiinterstate
iicommerce
(D) iiSubmit iia iilabel iisupplement iito iiFDA iiprior iito iidistribution iiof iiany iiblood iiproducts
iiin iiinterstate iicommerce ii- iiAnswers ii-Register iiwith iiFDA iiwithin iifive iidays iiafter
iibeginning iioperations iiand iiprovide iia iicurrent iiproduct iilist iiof iiall iiproducts
iimanufactured, iiprepared, iiprocessed iiand iidistributed
A iicompany iiis iiplanning iito iidevelop iia iisunscreen iicontaining iian iiingredient iiconsistent
iiwith iiits iipublished iimonograph iifor iimarketing iiwithin iithe iiUS. iiWhat iitype iiof iifiling
iidoes iithe iicompany iihave iito iisubmit? ii- iiAnswers ii-No iipremarket iiapproval iiis iirequired
while iicompany's iiNDA ii(New iiDrug iiApplication) iisubmission iiis iiunder iireview iiat iiFDA,
iithe iiUS iiPharmacopeial iiConvention iiissues iia iirevised iimonograph iiinvolving iia iiminor
iichange iito iithe iicompany's iiproduct. iiWhich iiof iithe iifollowing iiactions iiis iithe iiregulatory
iiprofessional's iiMOST iiappropriate iiresponse? ii- iiAnswers ii-Obtain iiapproval iifor
iisubmission iiand iisubmit iithe iichange iiin iithe iinext iiannual iireport
A iicompany iideveloping iian ii(unapproved) iidrug-device iicombination iiproduct iibut iiis iinot
iisure iito iiwhich iicenter iiit iishould iisubmit iiits iimarketing iiapplication. iiThe iicompany
iishould iifirst iisubmit. ii- iiAnswers ii-A iirequest iifor iiDesignation iito iithe iiOffice iiof
iiCombination iiPRoducts
An iiFDA iireviewer iicontacts iia iiregulatory iiprofessional iiwith iia iilengthy iilist iiof iiquestions
iiregarding iia iisubmitted iiapplication. iiSome iiof iithe iiinformation iiis iinot iireadily iiavailable
iiand iimay iirequire iiaddtional iidata iicollection. iiWhat iiis iithe iiBEST iicourse iiof iiaction iifor
iithe iiregulatory iiprofessional? ii- iiAnswers ii-Send iia iiletter iiwith iianticipated iiresponse
iitime
, To iiobtain iiapproval iifor iian iiANDA(Abbreviated iiNew iiDrug iiApplication), iia iicompany
iiMUST iimeet iiwhich iicriterion? ii- iiAnswers ii-Demonstrate iibioequivalence iibetween iithe
iiinnovator iidrug iiand iithe iiproposed iigeneric iidrug
Which iiof iithe iifollowing iichanges iican iibe iisubmitted iiwithout iian iiupdated iibatch iirecord
iifor iia iimodified-release iiproduct? ii- iiAnswers ii-Component iichange\: iideletion iiof
iicolor/flavor
A iidrug iimanufacturer iicreates iia iigame-based iisimulation iito iiassist iidiabetes iipatients
iiwith iimanagement iiof iitheir iiblood iiglucose iilevels iiand iito iimotivate iithem iito iiadhere iito
iitheir iimedication iischedules. iiThe iigame iiwill iibe iibased iion iia iipassword iiprotected
iiwebsite iithat iiill iibe iimade iiavailable iito iipatients iiwhen iian iiFDA-approved iidrug iiis
iiprescribed iito iithem. iiHow iiwill iithe iigame iimost iilikely iibe iiregulated iiby iiFDA? ii-
iiAnswers ii-It iiwill iinot iibe iian iiFDA iiregulated iiproduct
Within iihow iimany iidays iiafter iireceipt iiMUST iithe iiFDA iifile, iior iirefuse iito iifile, iiand
iiNDA? ii- iiAnswers ii-60
A iisponsor iiwishes iito iiobtain iipermission iifrom iiFDA iito iisubmit iian iiANDA(Abbreviated
iiNew iiDrug iiApplication) iifor iia iidrug iiproduct iithat iivaries iifrom iithe iiReference iiListed
iiDrug ii(RLD ii- iiReference iiListed iiDrug) iiin iiroute iiof iiadministration, iidosage iiform iior
iistrength. iiWhat iiprocess iishould iibe iiused iito iiapply iifor iithat iipermission iifrom iiFDA? ii-
iiAnswers ii-Suitability iiPetition
On iiMonday, iicommercial iistability iibatch iitesting iifor iian iiapproved iidrug iiproduced iiout-
of-specification iiresults. iiNo iiassignable iicause iihad iibeen iiidentified iias iiof iiWednesday.
iiWhat iiis iithe iibest iiaction iifor iithe iiregulatory iiprofessional iito iitake? ii- iiAnswers ii-Issue
iia iiField iiAlert
According iito iiICH iiQ10, iiimplementing iia iiPharmaceutical iiQuality iiSystem ii(PQS)
iiaddresses iiall iiof iithe iifollowing iiEXCEPT: ii
1) iiAPQS iican iibe iicertified iithrough iithe iiICH(International iiConference iion
iiHarmonisation iiof iiTechnical iiRequirements iifor iiRegistration iiof iiPharmasceuticals iifor
iiHuman iiUse) iiQ10 iiCert
2) iiManufacturing iiprocess iirobustness iiand iicontinuous
3) iiAPQS iireduces iithe iirisk iiof iiproduct iifailure
4) iiProvides iian iiopportunity iito iiincrease iiunderstanding ii- iiAnswers ii-A iiPQS iican iibe
iicertified iithrough iithe iiICH iiQ10 iiCertification iiProgramme, iireducing iithe iifrequency iiof
iiinspections
A iiclinical iiinvestigator iiwould iilike iito iiuse iian iiinvestigational iimedicinal iiproduct iito iitreat
iia iigravely iiill iipatient iiwho iidoes iinot iimeet iithe iiprotocol iiinclusion iicriteria. iiHowever, iiin
iithe iiexpert iiopinion iiof iithe iiclinical iiinvestigator, iithe iiproduct iiwould iibe iithe iibest
iioption iifor iithat iipatient. iiWhat iiaction iiis iiMOST iiappropriate iifor iithe iiclinical
iiinvestigator iito iitake? ii- iiAnswers ii-Obtain iiapproval iifrom iithe iiCA iifor iicompassionate
iiuse iiof iithe iiproduct iifor iithis iiparticular iipatient
Blood iiCenter iiABC iihas iijust iiopened iiin iia iiMidwestern iistate. iiIt iiplans iito iimanufacture
iiblood iiand iiblood iiproducts iifrom iivolunteer iiblood iidonors iiand iioffer iithese iiproducts
iifor iisale iito iilocal iidialysis iiclinics iiand iihospitals iiin iiother iistates. iiBlood iiCenter iiABC
iimust:
(A) iiRegister iiwith iiFDA iiwithin iifive iidays iiafter iibeginning iioperations iiand iiprovide iia
iicurrent iiproduct iilist iiof iiall iiproducts iimanufactured, iiprepared, iiprocessed iiand
iidistributed
(B) iiWait iito iidistribute iiany iiblood iiproducts iiuntil iithe iisuccessful iicompletion iiof iia iiGMP
iiinspection iiby iiFDA
(C) iiSubmit iian iiNDA iito iiFDA iiprior iito iidistribution iiof iiany iiblood iiproducts iiin iiinterstate
iicommerce
(D) iiSubmit iia iilabel iisupplement iito iiFDA iiprior iito iidistribution iiof iiany iiblood iiproducts
iiin iiinterstate iicommerce ii- iiAnswers ii-Register iiwith iiFDA iiwithin iifive iidays iiafter
iibeginning iioperations iiand iiprovide iia iicurrent iiproduct iilist iiof iiall iiproducts
iimanufactured, iiprepared, iiprocessed iiand iidistributed
A iicompany iiis iiplanning iito iidevelop iia iisunscreen iicontaining iian iiingredient iiconsistent
iiwith iiits iipublished iimonograph iifor iimarketing iiwithin iithe iiUS. iiWhat iitype iiof iifiling
iidoes iithe iicompany iihave iito iisubmit? ii- iiAnswers ii-No iipremarket iiapproval iiis iirequired
while iicompany's iiNDA ii(New iiDrug iiApplication) iisubmission iiis iiunder iireview iiat iiFDA,
iithe iiUS iiPharmacopeial iiConvention iiissues iia iirevised iimonograph iiinvolving iia iiminor
iichange iito iithe iicompany's iiproduct. iiWhich iiof iithe iifollowing iiactions iiis iithe iiregulatory
iiprofessional's iiMOST iiappropriate iiresponse? ii- iiAnswers ii-Obtain iiapproval iifor
iisubmission iiand iisubmit iithe iichange iiin iithe iinext iiannual iireport
A iicompany iideveloping iian ii(unapproved) iidrug-device iicombination iiproduct iibut iiis iinot
iisure iito iiwhich iicenter iiit iishould iisubmit iiits iimarketing iiapplication. iiThe iicompany
iishould iifirst iisubmit. ii- iiAnswers ii-A iirequest iifor iiDesignation iito iithe iiOffice iiof
iiCombination iiPRoducts
An iiFDA iireviewer iicontacts iia iiregulatory iiprofessional iiwith iia iilengthy iilist iiof iiquestions
iiregarding iia iisubmitted iiapplication. iiSome iiof iithe iiinformation iiis iinot iireadily iiavailable
iiand iimay iirequire iiaddtional iidata iicollection. iiWhat iiis iithe iiBEST iicourse iiof iiaction iifor
iithe iiregulatory iiprofessional? ii- iiAnswers ii-Send iia iiletter iiwith iianticipated iiresponse
iitime
, To iiobtain iiapproval iifor iian iiANDA(Abbreviated iiNew iiDrug iiApplication), iia iicompany
iiMUST iimeet iiwhich iicriterion? ii- iiAnswers ii-Demonstrate iibioequivalence iibetween iithe
iiinnovator iidrug iiand iithe iiproposed iigeneric iidrug
Which iiof iithe iifollowing iichanges iican iibe iisubmitted iiwithout iian iiupdated iibatch iirecord
iifor iia iimodified-release iiproduct? ii- iiAnswers ii-Component iichange\: iideletion iiof
iicolor/flavor
A iidrug iimanufacturer iicreates iia iigame-based iisimulation iito iiassist iidiabetes iipatients
iiwith iimanagement iiof iitheir iiblood iiglucose iilevels iiand iito iimotivate iithem iito iiadhere iito
iitheir iimedication iischedules. iiThe iigame iiwill iibe iibased iion iia iipassword iiprotected
iiwebsite iithat iiill iibe iimade iiavailable iito iipatients iiwhen iian iiFDA-approved iidrug iiis
iiprescribed iito iithem. iiHow iiwill iithe iigame iimost iilikely iibe iiregulated iiby iiFDA? ii-
iiAnswers ii-It iiwill iinot iibe iian iiFDA iiregulated iiproduct
Within iihow iimany iidays iiafter iireceipt iiMUST iithe iiFDA iifile, iior iirefuse iito iifile, iiand
iiNDA? ii- iiAnswers ii-60
A iisponsor iiwishes iito iiobtain iipermission iifrom iiFDA iito iisubmit iian iiANDA(Abbreviated
iiNew iiDrug iiApplication) iifor iia iidrug iiproduct iithat iivaries iifrom iithe iiReference iiListed
iiDrug ii(RLD ii- iiReference iiListed iiDrug) iiin iiroute iiof iiadministration, iidosage iiform iior
iistrength. iiWhat iiprocess iishould iibe iiused iito iiapply iifor iithat iipermission iifrom iiFDA? ii-
iiAnswers ii-Suitability iiPetition
On iiMonday, iicommercial iistability iibatch iitesting iifor iian iiapproved iidrug iiproduced iiout-
of-specification iiresults. iiNo iiassignable iicause iihad iibeen iiidentified iias iiof iiWednesday.
iiWhat iiis iithe iibest iiaction iifor iithe iiregulatory iiprofessional iito iitake? ii- iiAnswers ii-Issue
iia iiField iiAlert
According iito iiICH iiQ10, iiimplementing iia iiPharmaceutical iiQuality iiSystem ii(PQS)
iiaddresses iiall iiof iithe iifollowing iiEXCEPT: ii
1) iiAPQS iican iibe iicertified iithrough iithe iiICH(International iiConference iion
iiHarmonisation iiof iiTechnical iiRequirements iifor iiRegistration iiof iiPharmasceuticals iifor
iiHuman iiUse) iiQ10 iiCert
2) iiManufacturing iiprocess iirobustness iiand iicontinuous
3) iiAPQS iireduces iithe iirisk iiof iiproduct iifailure
4) iiProvides iian iiopportunity iito iiincrease iiunderstanding ii- iiAnswers ii-A iiPQS iican iibe
iicertified iithrough iithe iiICH iiQ10 iiCertification iiProgramme, iireducing iithe iifrequency iiof
iiinspections
A iiclinical iiinvestigator iiwould iilike iito iiuse iian iiinvestigational iimedicinal iiproduct iito iitreat
iia iigravely iiill iipatient iiwho iidoes iinot iimeet iithe iiprotocol iiinclusion iicriteria. iiHowever, iiin
iithe iiexpert iiopinion iiof iithe iiclinical iiinvestigator, iithe iiproduct iiwould iibe iithe iibest
iioption iifor iithat iipatient. iiWhat iiaction iiis iiMOST iiappropriate iifor iithe iiclinical
iiinvestigator iito iitake? ii- iiAnswers ii-Obtain iiapproval iifrom iithe iiCA iifor iicompassionate
iiuse iiof iithe iiproduct iifor iithis iiparticular iipatient
